meta
|
evidence
oncology
Living systematic review and meta-analysis
metastatic/advanced RCC (mRCC) - 1st line (L1)
11
mRCC - L1 - PDL1 negative
1
mRCC - L1 - PDL1 positive
4
immune chekpoint inhibitors
anti-PD-(L)1
atezolizumab based treatment
atezolizumab alone
atezolizumab plus bevacizumab
avelumab based treatment
avelumab plus axitinib
nivolumab based treatment
nivolumab plus cabozantinib
pembrolizumab based treatment
pembrolizumab plus axitinib
pembrolizumab plus lenvatinib
Immune checkpoint association
nivolumab plus ipilimumab
mTOR inhibitors
everolimus
lenvatinib plus everolimus
VEGF(R) inhibitor
lenvatinib
lenvatinib in association
versus all
vs VEGF(R) inhibitor
vs sunitinib
All patients
Age < 65y (younger)
Age > 65y
ECOG 0
ECOG 1
Gender, female
Gender, male
metastasis (bone)
metastasis (liver )
PD-L1 < 1%
PD-L1 > 1%
PDL1 (CPS < 1)
PDL1 (CPS >1)
previous nephrectomy (no)
previous nephrectomy (yes)
Risk favorable (IMDC)
Risk favorable (MSKCC)
Risk intermediate (IMDC)
Risk intermediate (MSKCC)
Risk poor (IMDC)
Risk poor (MSKCC)
smoker (current or former)
smoker (never)
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
study list
mapping
overview
meta-analysis
forest plot
NMA
excluded
button
bars
forest
bayes
pooled
summary
circles
deaths (OS)
deaths (OS) (extension)
DOR
DOR (extension)
objective responses (ORR)
objective responses (ORR) (extension)
PFS (extension)
progression or deaths (PFS)
AE (any grade)
AE (grade 3-4)
AE leading to death (grade 5)
AE leading to treatment discontinuation (any grade)
TRAE (any grade)
TRAE (grade 3-4)
TRAE leading to death (grade 5)
TRAE leading to discontinuation (any grade)
Adrenal insufficiency TRAE (grade 3-4)
Anaemia TRAE (grade 3-4)
Arthralgia TRAE (grade 3-4)
Asthenia TRAE (grade 3-4)
Chills TRAE (grade 3-4)
Colitis TRAE (grade 3-4)
Decreased appetite TRAE (grade 3-4)
Diabetes TRAE (grade 3-4)
Diarrhoea TRAE (grade 3-4)
Dysgeusia TRAE (grade 3-4)
Dyspepsia TRAE (grade 3-4)
Dysphonia TRAE (grade 3-4)
Dyspnoea TRAE (grade 3-4)
Epistaxis TRAE (grade 3-4)
Fatigue TRAE (grade 3-4)
Headache TRAE (grade 3-4)
Hepatitis TRAE (grade 3-4)
Hypertension TRAE (grade 3-4)
Hyperthyroidism TRAE (grade 3-4)
Hypophysitis TRAE (grade 3-4)
Hypothyroidism TRAE (grade 3-4)
Increase AST TRAE (grade 3-4)
Increased ALT TRAE (grade 3-4)
Infusion-related reactions TRAE (grade 3-4)
Mucosal inflammation TRAE (grade 3-4)
Myocarditis TRAE (grade 3-4)
Myositis TRAE (grade 3-4)
Nausea TRAE (grade 3-4)
Nephritis TRAE (grade 3-4)
Neutropenia TRAE (grade 3-4)
Palmar-plantar erythrodysaesthesia syndrome TRAE (grade 3-4)
Pancreatitis TRAE (grade 3-4)
Pneumonitis TRAE (grade 3-4)
Proteinuria TRAE (grade 3-4)
Pruritus TRAE (grade 3-4)
Rash TRAE (grade 3-4)
Severe skin reaction TRAE (grade 3-4)
Stomatitis TRAE (grade 3-4)
Thrombocytopenia TRAE (grade 3-4)
Thyroiditis TRAE (grade 3-4)
Uveitis TRAE (grade 3-4)
Vomiting TRAE (grade 3-4)
Weight decreased TRAE (grade 3-4)
Abdominal pain AE (grade 3-4)
Anaemia AE (grade 3-4)
Arthralgia AE (grade 3-4)
Asthenia AE (grade 3-4)
Back pain AE (grade 3-4)
Blood creatinine increased AE (grade 3-4)
Chills AE (grade 3-4)
Constipation AE (grade 3-4)
Cough AE (grade 3-4)
Decreased appetite AE (grade 3-4)
Diarrhoea AE (grade 3-4)
Dizziness AE (grade 3-4)
Dry skin AE (grade 3-4)
Dysgeusia AE (grade 3-4)
Dyspepsia AE (grade 3-4)
Dysphonia AE (grade 3-4)
Dyspnoea AE (grade 3-4)
Epistaxis AE (grade 3-4)
Fatigue AE (grade 3-4)
Headache AE (grade 3-4)
Hypertension AE (grade 3-4)
Hyperthyroidism AE (grade 3-4)
Hypothyroidism AE (grade 3-4)
Increase AST AE (grade 3-4)
Increased ALT AE (grade 3-4)
Mucosal inflammation AE (grade 3-4)
Nausea AE (grade 3-4)
Neutropenia AE (grade 3-4)
Oropharyngeal pain AE (grade 3-4)
Palmar–plantar erythrodysesthesia syndrome AE (grade 3-4)
Peripheral oedema AE (grade 3-4)
Proteinuria AE (grade 3-4)
Pruritus AE (grade 3-4)
Pyrexia AE (grade 3-4)
Rash AE (grade 3-4)
Stomatitis AE (grade 3-4)
Thrombocytopenia AE (grade 3-4)
Vomiting AE (grade 3-4)
Weight decreased AE (grade 3-4)
deaths (OS)
metastatic/advanced RCC (mRCC) - 1st line (L1)
metastatic/advanced RCC (mRCC) - 1st line (L1)
versus sunitinib
atezolizumab alone vs. sunitinib
1
-
atezolizumab plus bevacizumab vs. sunitinib
2
0.93
[0.76; 1.14], 1 RCT, I2=0%
inconclusive result
avelumab plus axitinib vs. sunitinib
1
0.80
[0.62; 1.03], 1 RCT, I2=0%
inconclusive result
nivolumab plus cabozantinib vs. sunitinib
1
0.60
[0.40; 0.89], 1 RCT, I2=0%
conclusive
unassessable degree of certainty
pembrolizumab plus axitinib vs. sunitinib
1
0.53
[0.38; 0.74], 1 RCT, I2=0%
conclusive
unassessable degree of certainty
pembrolizumab plus lenvatinib vs. sunitinib
1
0.66
[0.49; 0.88], 1 RCT, I2=0%
conclusive
unassessable degree of certainty
mRCC - L1 - PDL1 negative
metastatic/advanced RCC (mRCC) - 1st line (L1)
mRCC - L1 - PDL1 negative
versus sunitinib
atezolizumab plus bevacizumab vs. sunitinib
1
-
mRCC - L1 - PDL1 positive
metastatic/advanced RCC (mRCC) - 1st line (L1)
mRCC - L1 - PDL1 positive
versus sunitinib
atezolizumab alone vs. sunitinib
1
-
atezolizumab plus bevacizumab vs. sunitinib
2
0.84
[0.62; 1.14], 1 RCT, I2=0%
inconclusive result
avelumab plus axitinib vs. sunitinib
1
0.69
[0.58; 0.83], 1 RCT, I2=0%
unassessable degree of certainty
×
delta: difference in rate or median (if available)
×
Extraction panel open
An extraction panel is open